Clinical Trials
Clinical Trials
Sutro is currently advancing two wholly owned clinical-stage programs designed to provide patient benefit across multiple areas of unmet need. If you have any questions regarding our clinical trails, please contact clinicaltrials@sutrobio.com
STRO-001
ClinicalTrials.gov Identifier: NCT03424603
An Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies.
STRO–001-BM1 has received Orphan Drug designation for Multiple Myeloma patients.
Status: Recruiting
STRO-002
ClinicalTrials.gov Identifier: NCT03748186
An Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers.
STRO-002-GM1 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids.
Status: Recruiting
BN301
ClinicalTrials.gov Identifier: NCT05611853
an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Status: Not Yet Recruiting
Sutro Biopharma’s investigational products have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. The safety and efficacy of investigational products have not been established.